UROVANT SCIENCES LTD. Inactive Instrument
Urovant Sciences Ltd.
Equities
UROV
BMG9381B1081
Biotechnology & Medical Research
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Urovant Sciences Ltd. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for a range of urologic conditions. The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company's second product candidate, URO-902, is a gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
